These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 32538722)

  • 1. Gut Barrier Proteins Mediate Liver Regulation by the Effects of Serotonin on the Non-Alcoholic Fatty Liver Disease.
    Zhang K; Li X; Wang X; Zheng H; Tang S; Lu L; Ma X
    Curr Protein Pept Sci; 2020; 21(10):978-984. PubMed ID: 32538722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of tryptophan supplementation on diet-induced non-alcoholic fatty liver disease in mice.
    Ritze Y; Bárdos G; Hubert A; Böhle M; Bischoff SC
    Br J Nutr; 2014 Jul; 112(1):1-7. PubMed ID: 24708895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin reuptake transporter (SERT) plays a critical role in the onset of fructose-induced hepatic steatosis in mice.
    Haub S; Kanuri G; Volynets V; Brune T; Bischoff SC; Bergheim I
    Am J Physiol Gastrointest Liver Physiol; 2010 Mar; 298(3):G335-44. PubMed ID: 19713474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin signals through a gut-liver axis to regulate hepatic steatosis.
    Choi W; Namkung J; Hwang I; Kim H; Lim A; Park HJ; Lee HW; Han KH; Park S; Jeong JS; Bang G; Kim YH; Yadav VK; Karsenty G; Ju YS; Choi C; Suh JM; Park JY; Park S; Kim H
    Nat Commun; 2018 Nov; 9(1):4824. PubMed ID: 30446669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of serotonin in fatty acid-induced non-alcoholic fatty liver disease in mice.
    Ritze Y; Böhle M; Haub S; Hubert A; Enck P; Zipfel S; Bischoff SC
    BMC Gastroenterol; 2013 Dec; 13():169. PubMed ID: 24321090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enteric serotonin and oxytocin: endogenous regulation of severity in a murine model of necrotizing enterocolitis.
    Gross Margolis K; Vittorio J; Talavera M; Gluck K; Li Z; Iuga A; Stevanovic K; Saurman V; Israelyan N; Welch MG; Gershon MD
    Am J Physiol Gastrointest Liver Physiol; 2017 Nov; 313(5):G386-G398. PubMed ID: 28774871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonin receptor type 3 antagonists improve obesity-associated fatty liver disease in mice.
    Haub S; Ritze Y; Ladel I; Saum K; Hubert A; Spruss A; Trautwein C; Bischoff SC
    J Pharmacol Exp Ther; 2011 Dec; 339(3):790-8. PubMed ID: 21903748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indole-3-propionic acid inhibits gut dysbiosis and endotoxin leakage to attenuate steatohepatitis in rats.
    Zhao ZH; Xin FZ; Xue Y; Hu Z; Han Y; Ma F; Zhou D; Liu XL; Cui A; Liu Z; Liu Y; Gao J; Pan Q; Li Y; Fan JG
    Exp Mol Med; 2019 Sep; 51(9):1-14. PubMed ID: 31506421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of Gut Microbiota Composition by Serotonin Signaling Influences Intestinal Immune Response and Susceptibility to Colitis.
    Kwon YH; Wang H; Denou E; Ghia JE; Rossi L; Fontes ME; Bernier SP; Shajib MS; Banskota S; Collins SM; Surette MG; Khan WI
    Cell Mol Gastroenterol Hepatol; 2019; 7(4):709-728. PubMed ID: 30716420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of serotonin in the gut-liver neural axis ameliorates the fatty and fibrotic changes in non-alcoholic fatty liver.
    Ko M; Kamimura K; Owaki T; Nagoya T; Sakai N; Nagayama I; Niwa Y; Shibata O; Oda C; Morita S; Kimura A; Inoue R; Setsu T; Sakamaki A; Yokoo T; Terai S
    Dis Model Mech; 2021 Mar; 14(3):. PubMed ID: 33787507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract.
    Gershon MD
    Curr Opin Endocrinol Diabetes Obes; 2013 Feb; 20(1):14-21. PubMed ID: 23222853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Properties of myenteric neurones and mucosal functions in the distal colon of diet-induced obese mice.
    Reichardt F; Baudry C; Gruber L; Mazzuoli G; Moriez R; Scherling C; Kollmann P; Daniel H; Kisling S; Haller D; Neunlist M; Schemann M
    J Physiol; 2013 Oct; 591(20):5125-39. PubMed ID: 23940384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesenteric adipose tissue contributes to intestinal barrier integrity and protects against nonalcoholic fatty liver disease in mice.
    Wu Z; Tan J; Chi Y; Zhang F; Xu J; Song Y; Cong X; Wu N; Liu Y
    Am J Physiol Gastrointest Liver Physiol; 2018 Nov; 315(5):G659-G670. PubMed ID: 29902065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
    Mouries J; Brescia P; Silvestri A; Spadoni I; Sorribas M; Wiest R; Mileti E; Galbiati M; Invernizzi P; Adorini L; Penna G; Rescigno M
    J Hepatol; 2019 Dec; 71(6):1216-1228. PubMed ID: 31419514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral citrulline supplementation protects female mice from the development of non-alcoholic fatty liver disease (NAFLD).
    Sellmann C; Jin CJ; Engstler AJ; De Bandt JP; Bergheim I
    Eur J Nutr; 2017 Dec; 56(8):2519-2527. PubMed ID: 27496089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Essential roles of enteric neuronal serotonin in gastrointestinal motility and the development/survival of enteric dopaminergic neurons.
    Li Z; Chalazonitis A; Huang YY; Mann JJ; Margolis KG; Yang QM; Kim DO; Côté F; Mallet J; Gershon MD
    J Neurosci; 2011 Jun; 31(24):8998-9009. PubMed ID: 21677183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells.
    Reigstad CS; Salmonson CE; Rainey JF; Szurszewski JH; Linden DR; Sonnenburg JL; Farrugia G; Kashyap PC
    FASEB J; 2015 Apr; 29(4):1395-403. PubMed ID: 25550456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting peripheral serotonin synthesis reduces obesity and metabolic dysfunction by promoting brown adipose tissue thermogenesis.
    Crane JD; Palanivel R; Mottillo EP; Bujak AL; Wang H; Ford RJ; Collins A; Blümer RM; Fullerton MD; Yabut JM; Kim JJ; Ghia JE; Hamza SM; Morrison KM; Schertzer JD; Dyck JR; Khan WI; Steinberg GR
    Nat Med; 2015 Feb; 21(2):166-72. PubMed ID: 25485911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diammonium Glycyrrhizinate Protects against Nonalcoholic Fatty Liver Disease in Mice through Modulation of Gut Microbiota and Restoration of Intestinal Barrier.
    Li Y; Liu T; Yan C; Xie R; Guo Z; Wang S; Zhang Y; Li Z; Wang B; Cao H
    Mol Pharm; 2018 Sep; 15(9):3860-3870. PubMed ID: 30036479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin attenuates the onset of non-alcoholic fatty liver disease and affects intestinal microbiota and barrier in small intestine.
    Brandt A; Hernández-Arriaga A; Kehm R; Sánchez V; Jin CJ; Nier A; Baumann A; Camarinha-Silva A; Bergheim I
    Sci Rep; 2019 Apr; 9(1):6668. PubMed ID: 31040374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.